BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33604715)

  • 1. Time-varying effects of FOXA1 on breast cancer prognosis.
    Chen QX; Yang YZ; Liang ZZ; Chen JL; Li YL; Huang ZY; Weng ZJ; Zhang XF; Guan JX; Tang LY; Yun JP; Ren ZF
    Breast Cancer Res Treat; 2021 Jun; 187(3):867-875. PubMed ID: 33604715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
    Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
    J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    Rangel N; Fortunati N; Osella-Abate S; Annaratone L; Isella C; Catalano MG; Rinella L; Metovic J; Boldorini R; Balmativola D; Ferrando P; Marano F; Cassoni P; Sapino A; Castellano I
    BMC Cancer; 2018 Jul; 18(1):703. PubMed ID: 29970021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.
    BenAyed-Guerfali D; Dabbèche-Bouricha E; Ayadi W; Trifa F; Charfi S; Khabir A; Sellami-Boudawara T; Mokdad-Gargouri R
    Mol Biol Rep; 2019 Jun; 46(3):3247-3255. PubMed ID: 30941644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer.
    Zhou M; Gan XL; Ren YX; Chen QX; Yang YZ; Weng ZJ; Zhang XF; Guan JX; Tang LY; Ren ZF
    BMC Cancer; 2023 Aug; 23(1):743. PubMed ID: 37568077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
    Horimoto Y; Sasahara N; Sasaki R; Hlaing MT; Sakaguchi A; Saeki H; Arakawa A; Himuro T; Saito M
    Breast Cancer Res Treat; 2020 Aug; 183(1):41-48. PubMed ID: 32572714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
    Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
    Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
    Jing X; Liang H; Hao C; Hongxia L; Cui X
    Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
    BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 Protein Expression in ER
    Cheng TD; Yao S; Omilian AR; Khoury T; Buas MF; Payne-Ondracek R; Sribenja S; Bshara W; Hong CC; Bandera EV; Davis W; Higgins MJ; Ambrosone CB
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):379-385. PubMed ID: 31871111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles and correlation of FOXA1 and ZIC1 in breast cancer.
    Zhang YW; Ma J; Shi CT; Han W; Gao XJ; Zhou MH; Ding HZ; Wang HN
    Curr Probl Cancer; 2020 Oct; 44(5):100559. PubMed ID: 32115254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
    Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
    Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
    Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
    Wolf I; Bose S; Williamson EA; Miller CW; Karlan BY; Koeffler HP
    Int J Cancer; 2007 Mar; 120(5):1013-22. PubMed ID: 17163418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.